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Intravesical treatment of superficial bladder cancer with live bacillus
Calmette–Guérin (BCG) is an effective anti-cancer immunotherapy
(Morales, 1984). However, the use of live BCG organism has been
associated with serious undesirable side-effects such as fever, serum
sickness-like syndromes, granulomatous infection, sepsis and even
death (Lamm et al, 1992). Variability in viability and immuno-
genicity are other disadvantages associated with the use of live
bacteria as immunotherapeutic agents (Lagranderie et al, 1996;
Zlotta et al, 1997a,1997b), and this has led to the development of
other less toxic but effective biological response modifiers. A non-
viable mycobacterial cell wall extract (MCWE, US Patent No. 4744
984) derived from Mycobacterium phlei(M. phlei) has been shown
to have anti-cancer activity. Intravesical therapy with MCWE
formulated as a mineral oil emulsion (Regression®, Bioniche,
London, Ontario, Canada) has been shown to reduce cancer burden
in orthotopic and heterotopic murine bladder cancers (Kadhim et al,
1993; Chin et al, 1996) and in patients with carcinoma in situ of the
bladder (Morales and Chin, 1997).
MCWE is derived from M. phlei, a Gram-positive micro-
organism that is not a recognized pathogen for fish, amphibia,
birds and mammals. This ubiquitous mycobacteria can be found in
soil, on plants and in drinking water (Mallick et al, 1985;
Papapetropoulou et al, 1997). MCWE is a partially delipidated and
deproteinized macromolecular complex composed primarily of
carbohydrates, peptides and lipids. These molecules form the basis
of the two major components of the cell wall, peptidoglycan and
glycolipid (Chin et al, 1996). Although the mechanism of action of
MCWE against bladder cancer is unknown, M. phleihas been
reported to be a potent immunostimulator active against viral and
parasitic infections (Mallick et al, 1985; Tewari et al, 1996).
M. phleimycobacterial cell complex (MCC) is a cell wall
composition wherein the mycobacterial DNA is preserved and
complexed on the cell wall surface. We have found that MCC
preparations contain approximately 5–10% of M. phlei-derived
DNA, primarily in the form of short oligonucleotides (Filion et al,
1997). We have found that MCC has the ability to induce in vitro
and in vivo the synthesis of a number of human and mouse
cytokines (Filion et al, 1998). Because of the reported anti-cancer
activity of interleukin 12 (IL-12) towards some cancer cell lines
(Izquierdo et al, 1996; Stine et al, 1996) and the stimulatory
activity of granulocyte–macrophage colony-stimulating factor
(GM-CSF) on bladder cancer cell proliferation (Hawkyard et al,
1993), we felt it appropriate to determine whether MCC could
induce the synthesis of these anti- and procancer cytokines by
bladder cancer cells. We have also determined whether MCC
could induce IL-6, which has been shown to function either as a
growth factor (Okamato et al, 1997) or as an antiproliferative
factor for bladder cancer lines (Alexandroff et al, 1997).
In this report we have (a) evaluated the ability of MCC to induce
the synthesis of IL-6, IL-12 and GM-CSF by human HT-1197 and
HT-1376 bladder cancer cells, and (b) determined whether MCC
possesses direct cytostatic or cytotoxic activity towards these
cancer cells. Our results show that MCC does not have the
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proliferation and viability and an indirect effect mediated by the production of interleukin 12 (IL-12), a cytokine known to possess anti-cancer
activity. We have found that, although MCC is a potent inducer of IL-12 and IL-6 synthesis in monocytes and macrophages either in vitro or in
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with MCC is responsible for the induction of apoptosis. Our results indicate that MCC directly effects bladder cancer cells by inhibiting cellular
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Ontario, Canada N6M 1A3capacity to induce the synthesis of IL-12, IL-6 or GM-CSF by
bladder cancer cells. However, MCC is a potent inducer of IL-12
and IL-6, and a poor inducer of GM-CSF synthesis by monocytes
and macrophages. Furthermore, we show that MCC is able to
directly inhibit the proliferation of HT-1197 and HT-1376 transi-
tional cell carcinoma. MCC does not appear to be directly toxic
towards these cancer cells: it does, however, induce apotosis. We
found that M. phleiDNA associated with MCC is responsible for
the induction of apoptosis. Our results indicate that MCC may
possess a direct action against human bladder cancer cells after
intravesical administration by inducing apoptosis, and an indirect
action by stimulating cancer-infiltrating monocytes/macrophages
to synthesize IL-12.
MATERIALS AND METHODS
Cells
HT-1197 and HT-1376 are cancer cell lines developed from
anaplastic transitional cell carcinomas of the bladder taken from a
44-year-old Caucasian man (grade 4) and a 58-year-old Caucasian
woman (grade 3) respectively (Rasheed et al, 1977). HT-1197 and
HT-1376 cells were obtained from the American Type Tissue
Culture Collection (ATCC; Rockville, MD, USA) and were grown
in modified Eagle medium (MEM) supplemented with non-essen-
tial amino acids and vitamins and containing 10% fetal calf serum
(FCS) (MEM-FCS; all from Gibco Life Science, Burlington,
Ontario, Canada). Human monocytic THP-1 cells and murine
monocytic RAW 264.7 cells obtained from the ATCC were
cultured in RPMI-1640 medium supplemented with 10% FCS, 
2mML-glutamine and 20mMHepes (all from Gibco Life
Science). Murine macrophages were obtained from female CD1
mice injected i.p. with 1.5ml sterile Brewer’s thioglycolate broth
(Difco, Detroit, MI, USA). The peritoneal exudate (> 85%
macrophages) was harvested at day 4, washed by centrifugation in
Hanks’ balanced salt solution (HBSS) and seeded in 6-well flat
bottom microplates at 1.0 ´106 cells ml–1 in the medium described
for monocytes. The cells were allowed to adhere for 18h at 37°C
in an atmosphere of 5% carbon dioxide, after which non-adherent
cells were removed by gentle washing with warm medium. Murine
spleen cells were prepared by gentle teasing through sterile stain-
less-steel screens. Cell suspensions were layered on Lympholyte-
M cell separation media (CedarLane, Hornby, Ontario, Canada)
and centrifuged at 2200r.p.m. for 30min to remove red blood
cells and dead cells. The cells were cultured in the culture medium
described above. All cells were cultured at 37°C in an atmosphere
of 5% carbon dioxide.
Cytokine analysis
Cells were seeded at 1 ´106 cells ml–1 in 6-well flat-bottomed
tissue culture plates and treated with different concentrations of
MCC for 48h. Human (h) and murine (m) IL-6, IL-12 and GM-
CSF synthesis was measured after 48h by means of commercial
enzyme-linked immunosorbent assay (ELISA) (all from
BioSource, Camarillo, CA, USA, except murine GM-CSF which
was from R&D Systems, Minneapolis, MN, USA). The ELISA
sensitivities were: 8pg ml–1 for mIL-6, 2pg ml–1 for mIL-12, 
1pg ml–1 for mGM-CSF, 104fg ml–1 for hIL-6, 1pg ml–1 for 
hIL-12 and 1pg ml–1 for hGM-CSF.
Proliferation assay
HT-1197 and HT-1376 cells were incubated in 1.0ml MEM-FCS
at 3 ´105 cells in six-well flat-bottomed tissue culture plates with
MCC, Escherichia coli011:B4 lipopolysaccharide (LPS; Sigma-
Aldrich Canada, Oakville, Ontario, Canada) or recombinant 
hIL-12 (R&D Systems) for 20h at 37°C in an atmosphere of 5%
carbon dioxide. Cellular growth was measured by determination of
dimethylthiazoldiphenyltetrazolium bromide (MTT) reduction
(Mosman et al, 1983). Briefly, 100ml of MTT (Sigma-Aldrich)
dissolved in PBS at 5mg ml–1 was added to wells and incubated at
37°C for 4h. Acid-isopropanol (1.0ml of 0.04Nhydrochloric acid
in isopropanol) was then added, and reduced MTT was measured
at a wavelength of 570nm.
MCC toxicity determination
HT-1197 or HT-1376 cells were incubated in 1.0ml of MEM-FCS
at 3 ´105 cells in 6-well flat-bottomed tissue culture plates with
MCC for 48h. Lactate dehydrogenase (LDH) activity in the super-
natant was used as an indicator of cell death, and was determined
by means of a commercial kit (Sigma-Aldrich). Total LDH activity
was determined by incubating macrophages in 1.0% v/v Triton X-
100 in water to induce lysis, followed by vigorous agitation (Filion
and Phillips, 1997).
Analysis of apoptosis
HT-1197 or HT-1376 cells were incubated in 1.0ml MEM-FCS at
3 ´105 cells in six-well flat-bottomed tissue culture plates with 
1mg ml–1 of MCC or with 1ng ml–1 of IL-12 for up to 48h. After
incubation, non-adherent cells in the supernatant were collected 
by centrifugation at 200gfor 10min. The pellet or remaining
adherent cells were lysed with 0.5ml of hypotonic lysing buffer,
pH 7.5 (10mMTris buffer, 1mMEDTA, 0.2% Triton X-100). The
lysates were centrifuged at 13000gfor 10min and the super-
natants containing fragmented DNA were precipitated overnight at
–20°C in 50% isopropanol and 0.5Msodium chloride. The precip-
itates were collected by centrifugation and analysed by electro-
phoresis in 0.7% agarose gels for 3h at 100V (Newell, 1990).
Apoptosis was also determined by an ELISA (Calbiochem,
Cambridge, MA, USA) that detects nuclear mitotic apparatus
protein (NuMA) released from cells undergoing induced apoptosis
(Miller et al, 1993). Briefly, HT-1197 or HT-1376 cells were
treated as described above with MCC or with DNA extracted from
MCC. Media from the cell cultures was removed at 0, 3, 6, 24
and/or 48h, centrifuged at 200gfor 10min and the supernatant
was collected. The supernatant (100ml) was used for the determi-
nation of NuMA protein release by ELISA.
Isolation and treatment of DNA from MCC
Mycobacterial DNA was purified from MCC by conventional
phenol extraction and ethanol precipitation (Moore, 1995). MCC
or DNA extracted from MCC was incubated with 1U of DNAse I
(Gibco Life Sciences) for 1h at 25°C in 20mMtris-HCl 
(pH 8.4), 2mMmagnesium chloride and 50mMpotassium chlo-
ride. DNAse I was inactivated by the addition of EDTA (final
concentration 2.5mM) and the reaction mixture was heated for 10
min at 65°C. Digestion was confirmed by electrophoresis in 0.7%
agarose gels for 3h at 100V.
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Effect of MCC on cytokine synthesis
A number of cytokines are known to influence the regression or
the progression of cancer. IL-12 has been shown to have potent
anti-cancer activity by stimulating natural killer (NK) cells or T-
cells, and/or in blocking angiogenesis (Voest et al, 1995; Zitvogel
and Lotze, 1995; Stern et al, 1996) whereas GM-CSF has the
capacity to stimulate the unwanted proliferation of low-grade
bladder neoplasms (Hawkyard et al, 1993). IL-6 has the capacity
to stimulate the growth of bladder cancer cells (Okamoto et al,
1997) or to inhibit their proliferation (Alexandroff et al, 1997). It
has also been shown that bladder cancer cells are able to secrete
cytokines (De Reijke et al, 1993; Bevers et al, 1997). We have,
therefore, evaluated whether bladder cancer cells or immune
effector cells have the ability to synthesize IL-12, IL-6 or GM-C
SF in response to MCC. As shown in Figure 1, IL-12, IL-6 and
GM-CSF are not produced by HT-1197 and HT-1376 bladder
cancer cells in response to 1.0 mg ml–1 of MCC. However, at this
concentration, human THP-1 monocytes and murine macrophages
are able to produce significant amounts of IL-12 and IL-6 in
response to MCC treatment. Only murine RAW 264.7 cells were
able to synthesize GM-CSF. The i.p. administration of MCC to
female CD1 mice did not result in the synthesis of GM-CSF, but
did, however, induce the synthesis of IL-12 and IL-6 (Figure 2).
Similar results were obtained when MCC was administered i.v.
(data not shown).
Inhibition of cancer cell proliferation by MCC
The ability of MCC to directly influence the proliferation of HT-
1197 and HT-1376 bladder cancer cells was investigated. MCC is
able to inhibit the cellular proliferation of these bladder cancer
cells in a dose-dependent manner, whereas the control immuno-
stimulant LPS is without activity (Figure 3). IL-12 has been shown
to reduce the proliferative rate of several cancer cell lines
(Izquierdo et al, 1996; Stine et al, 1996). IL-12 does not inhibit 
the proliferation of either HT-1197 or HT-1376 bladder cancer
cells in the dose range 0.1–100 ng ml–1 (data not shown). To
explain this growth inhibition, we have evaluated whether MCC is
directly cytotoxic towards these cancer cells. Toxicity is character-
ized by the loss of plasma membrane integrity and release of the
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British Journal of Cancer (1999) 79(2), 229–235 © Cancer Research Campaign 1999
HT-1197
HT-1376
THP-1
Macrophages
Raw 264.7
Spleen cells
0 400 800 1200 1600 2000
Cytokine concentration
IL-12
IL-6
GM-CSF
Figure 1 MCC induces IL-6 and IL-12 synthesis only in monocytes and
macrophages. Human bladder cancer cell lines HT-1197 and HT-1376,
human monocytic THP-1 cells, murine monocytic RAW 264.7 cells, murine
macrophages or murine spleen cells were incubated at 1.0 ´ 106 cells ml–1
with 1.0 mg ml–1 of MCC for 48 h. IL-6, IL-12 and GM-CSF in the supernatant
were measured after 48 h by the appropriate ELISA. The results shown are
the means ± s.d. of three independent experiments
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Figure 2 MCC induces the synthesis of IL-6 and IL-12 without GM-CSF in
mice. Groups of five mice were injected i.p. with MCC (50.0 mg kg–1). Murine
IL-6, IL-12 and GM-CSF in the serum were quantified at 0, 3, 6, 8 and 24 h
after injection by the appopriate ELISA. The results shown are the 
means ± s.d. of two independent experiments
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Figure 3 MCC inhibits the cellular proliferation of human bladder cancer
cells. HT-1197 (A) and HT-1376 (B) cells were incubated at 3.0 ´ 105 cells
ml–1 with different concentrations of MCC or LPS for 24 h at 37°C, 5% carbon
dioxide. Cellular proliferation was measured by determination of MTT
reduction as described in the Materials and methods section. The results
shown are the means ± s.d. of three independent experimentscytoplasmic enzyme LDH (Wyllie et al, 1980). The release of
LDH into the culture supernatant has been used as an indicator of
cell death (Phillips et al, 1996), and human bladder cancer cells
have been shown to release LDH when treated with cytotoxic
agents (Rahman, 1994). As shown in Figure 4, MCC is not cyto-
toxic towards HT-1376 cells, as determined by the release of LDH
into the culture supernatant. Similar results were obtained with
HT-1197 cells (data not shown).
Induction of apoptosis by MCC
The lack of a direct cytotoxicity of MCC towards HT-1197 and
HT-1376 cancer cells in combination with the antiproliferative
activity suggested that MCC is an apoptosis inducer. Apoptosis, or
programmed cell death, is associated with nuclear DNA fragmen-
tation, the release of nuclear matrix proteins such as NuMA and
the loss of cell–substrate contact (Wyllie et al, 1980; Newell et al,
1990; Miller et al, 1993). The induction of apoptosis was demon-
strated by visualization of nucleosome-sized DNA fragments on
agarose gel electrophoresis and by the release of NuMA proteins.
MCC at 1.0 mg ml–1 was able to induce apoptosis in both HT-1197
and HT-1376 bladder cancer cells. Nucleosome-sized DNA frag-
ments characteristic of apoptosis were detected in detached HT-
1197 and HT-1376 bladder cancer cells after treatment with MCC
(Figure 5) MCC also induced the release of NuMA proteins in a
dose-related manner (Figure 6A). The release of NuMA increased
gradually from 3 h to 48 h; a concentration of 100 mg ml–1 MCC
being the most effective (Figure 6B and C). IL-12, which has 
been shown to induce apoptosis of several cancer cell lines (Stine
et al, 1996), was unable to induce apoptosis in HT-1197 and HT-
1376 bladder cancer cells, as demonstrated by an absence of
nucleosome-sized DNA fragments on agarose gel electrophoresis 
(Figure 5).
We have previously shown that MCC contains approximately
5–10% of M. phlei-derived DNA (Filion et al, 1997). We have
evaluated whether the DNA associated with MCC can induce
apoptosis of bladder cancer cells. DNA extracted from MCC is
able to induce the release of NuMA from HT-1376 cells, but to a
lesser extent than MCC (Figure 7). Treatment of MCC or M. phlei
DNA extracted from MCC by DNAse I, which has the capacity to
degrade single- and double-stranded DNA, significantly inhibits
the release of NuMA proteins (Figure 7), indicating that M. phlei
DNA plays a pivotal role in the induction of apoptosis in HT-1376
cancer cells. Similar results were obtained with HT-1197 cells
(data not shown).
DISCUSSION
In the present study, we have shown that MCC can act directly on
bladder cancer cells by inhibiting cellular proliferation through the
232 MC Filion et al
British Journal of Cancer (1999) 79(2), 229–235 © Cancer Research Campaign 1999
100
80
60
40
20
0
30
50
70
90
10
0.1 1.0 100.0 10.0 0 Triton X-100
MCC (mg ml–1)
%
 
L
D
H
 
r
e
l
e
a
s
e
d
Figure 4 MCC is not cytotoxic towards human bladder cancer cells. 
HT-1376 cells were incubated at 3.0 ´ 105 cells ml–1 with the indicated
concentrations of MCC for 48 h at 37°C, 5% carbon dioxide. Toxicity was
determined by the release of LDH activity into the supernatant. Total LDH
activity was determined by incubating the cells with 1.0% (v/v) Triton X-100.
The results shown are the means ± s.d. of three independent experiments
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Figure 5 MCC induces nuclear DNA fragmentation of human bladder cancer cells. HT-1197 and HT-1376 cells were incubated at 3.0 ´ 105 cells ml–1 with 
1.0 mg ml–1 of MCC or with 1.0 ng ml–1 of IL-12 at 37°C, 5% carbon dioxide. Adherent and non-adherent cells were lysed 48 h later. Cellular DNA was extracted,
precipitated and analysed by electrophoresis in 0.7% agarose gels for 3 h at 100 V as described in the Materials and methods section. A 123-bp DNA ladder
was used to evaluate the molecular weight of nucleosome-sized DNA. The results shown are for one experiment out of three; all give similar resultsinduction of apoptosis. MCC does not have the ability to induce
the synthesis of anti- (IL-12) or procancer (GM-CSF) cytokines by
bladder cancer cells but does have the ability to induce the
synthesis of significant amounts of the anti-cancer cytokine IL-12
by monocytes and macrophages either in vitro or in vivo.
Monocytes and macrophages have been shown to be present in 
the bladder wall of healthy individuals and have been shown to
accumulate around tumour islands in patients with bladder cancer
(El-Demiry et al, 1986; Ioachim-Velogiammi et al, 1994). IL-12
synthesized by these monocytes and macrophages may make a
significant contribution to the overall anti-cancer activity of MCC.
IL-12 has been shown to possess potent anti-cancer activity after
systemic or local administration in mice bearing a variety of
malignancies including melanomas, carcinomas, sarcomas, transi-
tional bladder carcinoma and lymphomas (Brunda et al, 1993;
Nastala et al, 1994; Noguchi et al, 1995; Zou et al, 1995, Chen et
al, 1997). IL-12 plays a role in the development of T-helper type-1
lymphocytes, stimulates g-interferon (IFN-g) synthesis, blocks
angiogenesis at sites of cancer growth and enhances NK cell and
cytotoxic T-cell activity (Voest et al, 1995; Stern et al, 1996;
Zitvogel and Lotze, 1996). Although IL-12 can also exert a direct
effect on some cancer cells by inhibiting cellular proliferation
through the induction of apoptosis (Stine et al, 1996), this does not
appear to be the case for the two bladder cancer cell lines used in
our study. The addition of recombinant human IL-12 to HT-1197
and HT-1376 bladder cancer cells had no direct effect on cellular
proliferation, and apoptosis was not induced by IL-12.
GM-CSF has been shown to induce the proliferation of bladder
cancer cells (Hawkyard et al, 1993). The results of our study show
that MCC does not induce, either in vitro or in vivo, the synthesis
of significant quantities of GM-CSF. BCG possesses the ability to
up-regulate the synthesis of IL-6 in bladder cancer cells
(Esuvaranathan et al, 1995; Sasaki et al, 1997). The role of IL-6 in
bladder cancer outcome is, however, unclear. IL-6 has been shown
to function either as a growth factor for bladder cancer lines
(Okamoto et al, 1997), or as an antiproliferative factor
(Alexandroff et al, 1997). We have found that although MCC at 1.0
mg ml–1 does not possess the ability to induce the synthesis of IL-6
by HT-1197 and HT-1376 bladder cancer cells, it does have the
ability to induce IL-6 by monocytes and macrophages either in
vitro or in vivo.
BCG has been shown to have antiproliferative effects on human
bladder cancer cells in vitro in the absence of any immune effector
cells (Pryor et al, 1995a, 1995b). Similar antiproliferative effects
of both heat-killed and viable BCG on a panel of human bladder
transitional cell carcinoma cell lines have also been described
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Figure 6 MCC induces the release of NuMA from human bladder cancer
cells. HT-1197 and HT-1376 cells were incubated at 3.0 ´ 105 cells ml–1 with
MCC at 37°C, 5% carbon dioxide. In (A), the release of NuMA from the cells
into the supernatant was detected by ELISA during incubation with different
concentrations of MCC for 48 h. In (B), the release of NuMA from HT-1197
cells, and in (C) the release of NuMA from HT-1376 cells into the
supernatant, was determined at 0, 3, 8, 24 and 48 h after treatment with 
1 mg ml–1 or 100 mg ml–1 of MCC. The results shown are the means ± s.d. of
three independent experiments
0
25
15
10
20
5
35
40
30
0.1 1 100 10 0
MCC concentration (mg ml
–1)
N
u
M
A
 
(
U
 
m
l
–
1
)
HT-1197
HT-1376
A
B
0
25
15
10
20
5
35
40
30
12 24 48 36 0
N
u
M
A
 
(
U
 
m
l
–
1
)
No MCC
MCC (1 mg ml
–1)
MCC (100 mg ml–1)
Time of incubation (h)
C
0
15
10
25
5
N
u
M
A
 
(
U
 
m
l
–
1
)
No MCC
MCC (1 mg ml–1)
MCC (100 mg ml
–1)
Time of incubation (h)
20
01 22 4 3 6 4 8
Figure 7 DNA extracted from MCC induces the release of NuMA. HT-1376
cells (3.0 ´ 105 cells ml–1) were incubated for 48 h at 37°C, 5% carbon dioxide
with MCC or DNA purified from MCC (1 mg ml–1). In some experiments, MCC
or DNA purified from MCC were treated by DNAse I (1 U) as described in the
Materials and methods section before their addition to HT-1376 cells. After
48 h, supernatants were collected (100 ml) and the release of NuMA released
was quantified by ELISA as described in the Materials and methods section.
The results shown are the means ± s.d. of two independent experiments
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DNAse I(Jackson et al, 1994). However, the mechanism of cellular growth
inhibition has not been identified in these studies (Jackson et al,
1994; Pryor et al, 1995a). Sasaki et al (1997) have shown that the
ability of BCG to inhibit the growth of T24 cells was not related to
the induction of apoptosis. Other groups have reported an indirect
induction of apoptosis in bladder cancer cells by BCG. Shemtov et
al (1995) have shown that the human bladder cancer cell line T24
can undergo apoptosis after contact with lymphocyte-activated
killer cell (LAK cells), whereas Kudoh et al (1997) have found
that BCG-activated lymphocytes are able to induce apotosis of
T24 cells via cytokine synthesis. In this study, we have found that
the antiproliferative activity of MCC was mediated by the direct
induction of apoptosis of human bladder cancer cells and not by a
cytotoxic effect. To our knowledge, the present study is the first
demonstration of the ability of a mycobacterial cell wall prepara-
tion to directly induce apoptosis in cancer cells. We have addition-
ally demonstrated that the apoptosis induced by MCC is related to
the presence of mycobacterial DNA in the preparation, and that M.
phlei DNA has intrinsic apoptosis-inducing activity.
Apoptosis plays an important role in the activity of many anti-
cancer chemotherapeutic agents and in their effectiveness in the
treatment of cancer (Dive et al, 1992). It has been shown, however,
that bladder carcinomas are resistant to a number of anti-cancer
drugs (Lamm et al, 1995). Our data show that MCC not only
directly induces apoptosis in HT-1197 bladder cancer cells, which
are sensitive to doxorubicin, but also directly induces apoptosis in
HT-1376 bladder cancer cells, which have been shown to be
resistant to several apoptosis-inducing drugs such as cisplatin and
mitomycin C (Kawasaki et al, 1996; Mizutani et al, 1997). Chemo-
therapy of bladder cancer has been shown to be effective in low-
grade cancers, whereas immunotherapy with BCG appears to be
optimally effective in higher grade cancers (Lamm, 1995).
Although highly effective regardless of tumour grade, BCG treat-
ment is preferably reserved for the most aggressive cancer because
of its safety profile (Lamm, 1995). MCC, which appears to possess
both a chemotherapeutic-like action against human bladder cancer
cells by inducing apoptosis and an indirect BCG-like action by
stimulating immune effector cells, has significant promise for the
treatment of both low-grade and high-grade bladder cancers.
Because mycobacterial cell wall extracts do not contain live
bacteria, their safety profile is better (Morales and Chin, 1997).
Further studies investigating the role of apoptosis and IL-12
synthesis induced by MCC using in vivo animal models will be
required to clarify the mechanisms implicated in the anti-cancer
activity of MCC. MCC and M. phlei DNA associated with MCC
are currently being analysed to determine their proapoptotic
activity on a number of other bladder cancer cell lines and on
freshly derived primary cultures of human bladder carcinoma cells.
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